MNKD 241220 6.50P (MNKD241220P6500) Stock Options, News & Quotes

US OptionsDetailed Quotes

MNKD241220P6500

Watchlist

0.50
0.000.00%

15min DelayTrading Dec 18 15:26 ET

0.00High0.00Low

Intraday

5D
Daily

News

MannKind Analyst Ratings
BenzingaDec 19 10:50 ET · Ratings
RBC Upgrades MannKind on Royalty Revenue, Orphan Lung Pipeline
TipRanksDec 19 06:20 ET
Express News | MannKind Corp : RBC Raises to Outperform From Sector Perform; Raises Target Price to $10 From $7
ReutersDec 19 00:56 ET
MannKind Corporation Reduces Debt by $194 Million and Strengthens Cash Position to Over $180 Million
Quiver QuantitativeDec 18 07:11 ET
Express News | MannKind Corp: Debt Reduced by $194 Mln
ReutersDec 18 07:01 ET
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
GlobeNewswireDec 18 07:00 ET

Comments

Stock_Drift

Dec 16 05:17

$MannKind (MNKD.US)$

Jaguar8

Dec 16 05:09

NEWS

$MannKind (MNKD.US)$
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
4 minutes ago, 3:05 AM PST
Via GlobeNewswire
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025
Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression
MannKind (MNKD) announced six-month results from its Phase 3 INHALE-1 study of Afrezza (inhaled insulin) in children and adolescents aged 4-17...

BelleWeather

Nov 22 05:30

Housekeeping continued…

Surpassed target price and am focusing elsewhere.

Share Your Profit/Loss

BelleWeather

Oct 25 14:15

Scaling out

of LETFs and contracts…

Share Your Profit/Loss

BelleWeather

Oct 18 21:03

MannKind

I think this company still has room to grow and may be undervalued, however it is next to being scaling out for other opportunities as the space is crowded and many new therapies have advanced.

Share Your Profit/Loss